|
Dr. Kroeger joined Aurora in 2003 and became a Principal in 2005. Dr. Kroeger focuses on biopharmaceutical and medical device opportunities and brings a broad spectrum of business, clinical and scientific expertise to Aurora’s investments in these sectors. Dr. Kroeger led or co-led syndicated investments in Cardioxyl Pharmaceuticals, Hyberbranch Medical, and Neotropix, and led Aurora’s investments in Cardiofocus and Paringenix. Prior to joining Aurora, Chris trained in general surgery at Brigham and Women’s Hospital/Harvard Medical School where he was involved in the medical and surgical care of transplant, trauma, vascular, cardiac and general surgical patients. He has over seven years of clinical experience in both academic and community hospital practices, and is a licensed physician in North Carolina. Dr. Kroeger also has significant basic science research experience primarily in signal transduction, including work on the molecular biology and genetics of apoptosis, and the transcriptional regulation of Interleukin-2 in human T-cells. Dr. Kroeger previously worked with Arthur D. Little/Decision Resources, providing industry and technology analysis to biotechnology and pharmaceutical companies. Additionally, while attending business school, Chris worked in Corporate Development at Genzyme. Dr. Kroeger received a B.A. in Biology from Harvard University, his M.D. from Stanford University School of Medicine and an MBA from Harvard Business School. Dr. Kroeger serves on the boards of Cardiofocus, Hyperbranch Medical Technologies, Neotropix and ParinGenix, and serves as an observer on the boards of Aldagen, Argos, Metastatix and Regado. Chris also serves on the Johns Hopkins Technology Alliance. | 